Silexion Therapeutics Reports Breakthrough Preclinical Data For SIL-204 In Pancreatic Cancer Jan 28, 2025•RTTNews Biotech Silexion Demonstrates Synergy Of SIL-204 With Key Chemotherapies In KRAS-Mutated Pancreatic Cancer Jan 16, 2025•RTTNews ...
Dividend-focused ETFs provide stability and income opportunities during downturns and periods of economic uncertainty. Kate Stalter andRachel McVearry April 7, 2025 Investing 10 Best Artificial Intelligence Stocks Countless companies stand to benefit from AI, but these stocks have AI and automation as...
Silexion Therapeutics Corp.(NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today reported its financial results for the third quarter endedSeptember 30, 2024, and provided an update on recent bu...
Find the latest SLXN stock news. View the Silexion Therapeutics news and quotes for today, invesment news based on TipRanks market-leading research tools.
Silexion Therapeutics LTD (SLXN)1.38 0.12 (9.52%) 03-12 16:00 Open: 1.28 High: 1.381 Volume: 539,171 Pre. Close: 1.26 Low: 1.25 Market Cap: 12(M)Technical analysis 2025-03-12 4:50:32 PMShort term Mid term Targets 6-month : 2.07 1-year : 2.42 Resists First : 1.77 Second...
生物制药公司Silexion Therapeutics Corp(NASDAQ:SLXN)市值为1077万美元,该公司周一宣布已与EarlyBirdCapital, Inc.达成协议,退还一笔可转换本票。该票据日期为2024年8月15日,本金金额为125万美元,原定于2025年12月31日到期,可由EarlyBirdCapital自行决定转换为普通股。该公司股票目前交易价格为1.28美元,过去一年股价...
Silexion Therapeutics股票因与Catalent在癌症治疗方面的合作而暴涨52% RTTNews04/24 02:46 12只医疗保健股票在周三的盘中交易中波动 收益者Ensysce Biosciences (纳斯达克:ENSC) 的股价在周三的常规交易中上涨了81.3%,达到$3.39。该公司的市值为$470万。Sonoma Pharmaceuticals (纳斯达克: Benzinga04/24 01:05 Silex...
用富途牛牛查看Silexion Therapeutics(SLXN)的股票價格、即時報價、最新新聞、歷史走勢圖、財務信息和行情。
近日,Silexion Therapeutics Corp (NASDAQ:SLXN)宣布其股东批准了反向拆股。这一决定是在11月12日由于缺乏法定人数而初次休会后,于周二重新召开的特别股东大会上做出的。 在会议期间,公司29.5%的流通普通股出席,经过半小时等待后达到法定人数,会议得以继续进行。唯一的议程项目是以1比9的比例对公司普通股进行反向拆...
Silexion Therapeutics Corp. advanced stock charts by MarketWatch. View SLXN historial stock data and compare to other stocks and exchanges.